In cases of reduced LV systolic function, standard heart failure GDMT typically includes beta-blockers, renin–angiotensin system blockade with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or a neprilysin inhibitor–angiotensin receptor combination (sacubitril/valsartan). This evidence concerns the gene REN and heart failure.